Is Brookfield (TSX:BN) Pricey On Its Insurance Expansion Push?

Brookfield (TSX:BN) is putting its growing insurance platform at the center of its long term plan, with more than $180b in insurance assets and a goal of reaching $350b by 2030.

See our latest analysis for Brookfield.

Brookfield's recent focus on insurance arrives after a mixed share price stretch, with the stock down 2.6% year to date yet supported by a strong 3 year total shareholder return of 102.9%. This suggests long term momentum remains intact despite shorter term swings.

If you are weighing Brookfield against other opportunities, this is a good moment to see what else is moving and scan 3 top founder-led companies

Brookfield is leaning hard into insurance at the same time the share price has stalled in the short term but delivered strong multi year gains. Does the current valuation still give buyers a clear edge on risk and reward?

Preferred P/E of 85.3x: Is it justified?

Brookfield currently trades on a P/E of 85.3x, which is high relative to many capital markets stocks. The key question is what investors think they are paying for at that level.

The P/E ratio compares the current share price to earnings per share and effectively shows how much investors are willing to pay today for each dollar of earnings. For a diversified asset manager like Brookfield, a higher P/E can sometimes signal expectations for stronger earnings resilience, higher fee based income, or improved profitability from its mix of real assets and insurance activities.

Recent data shows some mixed signals for Brookfield. Earnings grew very strongly over the past year, with 161.2% earnings growth and an improvement in net profit margins from 0.5% to 1.5%. At the same time, earnings have declined by 35.1% per year over the past 5 years, and the stock is marked as expensive both compared to the Canadian Capital Markets industry P/E of 9.7x and a peer average P/E of 41.3x. That combination suggests the market is putting a rich price on recent improvement and potential future profitability, while the longer history is less supportive of such a premium.

Compared with the wider Canadian market and its own industry, Brookfield’s 85.3x P/E stands out clearly. It is more than 8 times the Canadian Capital Markets industry average of 9.7x and roughly double the peer average of 41.3x, so the valuation gap is wide rather than marginal. For investors, that raises a simple framing question: whether the recent earnings rebound and quality of earnings are strong enough to justify such a premium compared to both peers and the broader market.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 85.3x (OVERVALUED)

However, Brookfield’s revenue contraction of 97.4% and the high 85.3x P/E leave little room for disappointment if earnings or insurance growth fall short.

Find out about the key risks to this Brookfield narrative.

Next Steps

With Brookfield trading on such a rich P/E and investors split between concerns and optimism, this is the time to move fast and stress test your own thesis using the full picture of 2 key rewards and 3 important warning signs

Looking for more Brookfield sized investment ideas?

If Brookfield has sharpened your focus on where capital can work harder, do not stop here. Use powerful stock screeners to uncover what others might overlook.

• Target potential mispricing by scanning the market for companies that mix quality with appealing valuations through the 6 high quality undervalued stocks.
• Prioritize stability and financial strength by checking stocks filtered through the solid balance sheet and fundamentals stocks screener (11 results).
• Get ahead of the crowd by reviewing a screener containing 10 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com